Sanofi’s Experimental Dengue Vaccine Lowers Hospitalization Risk In Older Children, Data Show

Agence France-Presse: Data analyses back Sanofi dengue vaccine
“A dengue vaccine candidate by French drugmaker Sanofi protects more than three quarters of participants, an analysis found Monday. The experimental drug allowed 80.8 percent of children aged nine and older to avoid hospitalization, according to three trials analyzed by the New England Journal of Medicine…” (7/27).

CIDRAP News: Dengue vaccine may drop hospital risk in older kids but not younger
“Long-term follow-up results in three large phase 2 and 3 trials suggest that an experimental dengue vaccine, CYD-TDV, lowers dengue-related hospitalization risk in older children but may increase the risk in younger ones, according to a report [Monday] in the New England Journal of Medicine…” (Roos, 7/27).

Reuters: Sanofi says new data analyses support its dengue vaccine
“…Protection against severe dengue reached 93 percent, while prevention of hospitalization due to the disease reached 80 percent in the volunteers, who were aged nine and above, Sanofi said in a statement. ‘The dengue vaccine candidate has the potential to significantly reduce disease burden in endemic countries,’ Sanofi said…” (Regan, 7/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.